The authors measured relative risks of second contralateral breast cancer (CBC) and breast cancer death using Fine and Gray multivariable regression modeling adjusted for the competing risk of death and death from another cause, respectively, and potential confounding factors. A., Hollestelle, A., Hoppe, R., Hopper, J. L., Hunter, D. J., Jacot, W., Jakubowska, A., John, E. M., Jung, A. Y., Kaaks, R., Khusnutdinova, E., Koppert, L. B., Kraft, P., Kristensen, V. N., Kurian, A. W., Lambrechts, D., Le Marchand, L., Lindblom, A., Luben, R. N., Lubiski, J., Mannermaa, A., Manoochehri, M., Margolin, S., Mavroudis, D., Muranen, T. A., Nevanlinna, H., Olshan, A. F., Olsson, H., Park-Simon, T. W., Patel, A. V., Peterlongo, P., Pharoah, P. D., Punie, K., Radice, P., Rennert, G., Rennert, H. S., Romero, A., Roylance, R., Rdiger, T., Ruebner, M., Saloustros, E., Sawyer, E. J., Schmutzler, R. K., Schoemaker, M. J., Scott, C., Southey, M. C., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Teras, L. R., Thomas, E., Tomlinson, I., Troester, M. A., Vachon, C. M., Wang, Q., Winqvist, R., Wolk, A., Ziogas, A., Michailidou, K., Chenevix-Trench, G., Bachelot, T., Schmidt, M. K. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Because it may have medical and psychosocial complications, a better understanding of its use and outcomes is essential to optimizing cancer care.To compare use of and mortality after bilateral mastectomy, breast-conserving therapy with radiation, and unilateral mastectomy.Observational cohort study within the population-based California Cancer Registry; participants were women diagnosed with stages 0-III unilateral breast cancer in California from 1998 through 2011, with median follow-up of 89.1 months.Factors associated with surgery use (from polytomous logistic regression); overall and breast cancer-specific mortality (from propensity score weighting and Cox proportional hazards analysis).Among 189,734 patients, the rate of bilateral mastectomy increased from 2.0% (95% CI, 1.7%-2.2%) in 1998 to 12.3% (95% CI, 11.8%-12.9%) in 2011, an annual increase of 14.3% (95% CI, 13.1%-15.5%); among women younger than 40 years, the rate increased from 3.6% (95% CI, 2.3%-5.0%) in 1998 to 33% (95% CI, 29.8%-36.5%) in 2011. The similar overall PV frequencies for ILC and IDC suggest that cancer histology should not influence the decision to proceed with genetic testing. Performance of BRCA1/2 mutation prediction models in Asian Americans. Worry in the long-term survivorship period was higher among those with unmet need for discussion (48.7% v 24.9%; P Our model maintains a Markov belief about the effectiveness of the different therapies and updates it as therapies are administered and tumor images are observed, reflecting tumor response. In a separate model, the odds ratios were 1.21 (95% CI, 0.54 to 2.68) and 0.90 (95% CI, 0.50 to 1.62) for pathogenic variant and variant of uncertain significance, respectively, versus a negative test (the reference group).Compared with BRCA1/2 testing alone, multigene panel testing was not associated with increased cancer worry after diagnosis of breast cancer. We examined patient reports of cancer worry by test type and results in 1,063 women who linked to a genetic test and reported undergoing testing.More than half of the sample (n = 640; 60.2%) received BRCA1/2-only testing versus 423 patients (39.8%) who had a multigene panel. In MEC, smoking cessation after IPLC diagnosis was associated with an 83% reduction in SPLC risk (HR 0.17; P<0.001).Tobacco smoking is a risk factor for SPLC. In the free testing arm, 20 of 56 eligible patients participated (35.7% of eligible respondents) and they invited 28 relatives: 12 relatives enrolled and 10 ordered testing. The influence of demographic and pathologic features was used in a multivariable logistic regression model to compare expected with observed HER2-positive percentages by region.There was significant geographic variation by California counties (11.6%-26%). The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer. Minority patients were significantly more likely to have unmet need for discussion (failure to discuss genetic testing with a health professional when they had a strong desire for testing): odds ratios of 1.68, 2.44, and 7.39 for blacks, English-speaking Latinas, and Spanish-speaking Latinas compared with whites, respectively. Adding BMI or height to weight did not improve fit (AIC=0.90 and 0.83, respectively; both P=0.3). Kim, S. M., Hatami, F., Harris, J. S., Kurian, A. W., Ford, J., King, D., Scalari, G., Giovannini, M., Hoyler, N., Faist, J., Harris, G. Comparative Analysis of Bio-Medical Imaging at 3.7 Terahertz with a High Power Quantum Cascade Laser, Kim, S. M., Hatami, F., Gu, A., Kurian, A. W., et al, A clinic-based study of BRCA1/2 mutation epidemiology in Asians, Kurian, A. W., Chun, N. M., Millls, M. A., et al, Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Wu, A. H., Kurian, A. W., Kwan, M. L., John, E. M., Lu, Y., Keegan, T. H., Gomez, S. L., Cheng, I., Shariff-Marco, S., Caan, B. J., Lee, V. S., Sullivan-Halley, J., Tseng, C., Bernstein, L., Sposto, R., Vigen, C. Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. A., Terry, M. B., Tomlinson, I., Troester, M. A., Truong, T., Vachon, C. M., van Veen, E. M., Vijai, J., Wang, S., Wendt, C., Winqvist, R., Wolk, A., Ziogas, A., Dunning, A. M., Pharoah, P. D., Easton, D. F., Zheng, W., Kraft, P., Chang-Claude, J. Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. Taniya Wright Death. For a hypothetical cohort of 100,000 persons, we estimated cancer-related deaths under assumptions that cancers diagnosed at stage IV were diagnosed at earlier stages.Stage IV cancers represented 18% of all estimated diagnoses but 48% of all estimated cancer-related deaths within 5 years. Better risk communication by clinicians may translate to better risk comprehension among patients and to improvements in QoL. Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care. For more information, please contact Pei-Jen Chang, (650) 725 - 0866. Weldon, C. B., Liang, S., Phillips, K. A., Douglas, M. P., Scheuner, M., Kurian, A. W., Schaa, K., Roscow, B., Erwin, D., Trosman, J. R. The Impact of COVID-19 on Patients With Cancer: A National Study of Patient Experiences. View details for DOI 10.1001/jamaoncol.2020.7995. This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel Shariff-Marco, S. n., Ellis, L. n., Yang, J. n., Koo, J. n., John, E. M., Keegan, T. H., Cheng, I. n., Monroe, K. R., Vigen, C. n., Kwan, M. L., Lu, Y. n., Bernstein, L. n., Wu, A. H., Gomez, S. L., Kurian, A. W. Abstract IA50: Genetic testing, treatment and mortality after diagnosis of breast cancer or ovarian cancer: The SEER-GeneLINK Initiative, Health Disparities in Germline Genetic Testing for Cancer Susceptibility. Those who endorsed a maladaptive mindset (Cancer is a Catastrophe) reported lower health-related quality of life (HRQOL) compared with those who did not hold this belief (p < .001). Over the past several decades, the disease's incidence has risen worldwide, increasing in developing and developed countries. View details for DOI 10.6004/jnccn.2021.0001, View details for Web of Science ID 000587855200005, View details for Web of Science ID 000607202800270, View details for Web of Science ID 000560368307247, View details for Web of Science ID 000560368303141, View details for Web of Science ID 000560368301028, View details for Web of Science ID 000560368301153, View details for Web of Science ID 000560368301027, View details for Web of Science ID 000560368301071, View details for Web of Science ID 000546262400156. Women are more likely to experience worse cancer-related financial outcomes than men. Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., Kurian, A. W. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. Friese, C. R., Harrison, J. M., Janz, N. K., Jagsi, R., Morrow, M., Li, Y., Hamilton, A. S., Ward, K. C., Kurian, A. W., Katz, S. J., Hofer, T. P. Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Idos, G., Roth, K. G., Naghi, L., Ricker, C., Culver, J., Sturgeon, D., Kingham, K., Koff, R., Chun, N. M., Rowe-Teeter, C., Hartman, A., Allen, B., Evans, B., Mills, M., Hong, C., McDonnell, K., Ladabaum, U., Ford, J. M., Gruber, S. B., Kurian, A. W. Expanded yield of multiplex panel testing in fully accrued prospective trial. The rate of final lumpectomy increased by 13% from 2013 to 2015, accompanied by a decrease in unilateral and bilateral mastectomy (P=.002). Kurian, A. W., Hughes, E., Handorf, E., Gutin, A., Allen, B., Hartman, A., Hall, M. J. Multivariable logistic regression analysis was performed to describe associations of CNAs with these two groups of DCIS.We examined 271 patients with DCIS (120 that did not develop IBC and 151 with concurrent IBC) for the presence of 1q, 8q24 and 11q13 copy number gains. The current trial, BNIT-BR-003, will evaluate the safety and biological activity of a fixed Choi, Y. H., Terry, M. B., Daly, M. B., MacInnis, R. J., Hopper, J. L., Colonna, S. n., Buys, S. S., Andrulis, I. L., John, E. M., Kurian, A. W., Briollais, L. n. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Among ovarian cancer patients, cancer-specific mortality was lower with PVs in BRCA2 (HR=0.35, 95% CI=0.25-0.49) and genes other than BRCA1/2 (HR=0.47, 95% CI=0.32-0.69). characteristics typical of the poly (ADP-ribose) polymerase (PARP) inhibitor class. Wallner, L. P., Li, Y., McLeod, M., Gargaro, J., Kurian, A. W., Jagsi, R., Radhakrishnan, A., Hamilton, A. S., Ward, K. C., Hawley, S. T., Katz, S. J. Each was staged as T1N0M0. Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer. We searched key electronic databases to identify studies evaluating hereditary cancer cascade testing. View details for DOI 10.1007/s10689-007-9171-7, View details for Web of Science ID 000253712200022. Patients seeing an oncologist who was one standard deviation above the mean use of RS testing had over two-times higher odds of receiving RS (2.47, 95% CI 1.47-4.15), but a parallel estimate of the association of oncologist with the odds of receiving chemotherapy was much smaller (1.39, CI 1.03-1.88).Clinical algorithms have markedly reduced variation in chemotherapy use across oncologists. Second breast cancers are rare, and their reduction should be weighed against the harms associated with BLM. Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer, Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer, Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. Results were adjusted for multiple hypothesis testing. The immune system is critical in modulating cancer progression, but knowledge of immune composition, phenotype, and interactions with tumor is limited. For more information, please contact Amy Isaacson, 650-723-0501. Larger studies are needed to identify risk factors and prognostic significance associated with atypia and non-fluid-yielding ducts in high-risk populations, and define their role as biomarkers. Relative to high-socioeconomic status (SES) non-Hispanic Whites, we observed less anthracycline and taxane use by SES non-Hispanic Whites (OR 0.63, 95 % CI 0.49-0.82) and American Indians (OR 0.23, 95 % CI 0.06-0.93), and more anthracycline use by high-SES Asians/Pacific Islanders (OR 1.72, 95 % CI 1.02-2.90). Multivariate models evaluated correlates of missing work for >1 month and stopping work altogether versus missing work for 1 month.In this diverse sample, most patients (62%) underwent lumpectomy; 16% underwent unilateral mastectomy (8% with reconstruction); and 23% underwent bilateral mastectomy (19% with reconstruction). Worst Of The Worst Gigantic Blackheads Popping Videos 2018. BOADICEA overpredicted mutations in African Americans and older NHWs, and BRCAPRO underpredicted in Hispanics. also hope to understand more about the experience of individuals and families who undergoing Across pathogenic variants, annual mammography alone from 40 to 74 years was estimated to reduce breast cancer mortality by 36.4% (34.6%-38.2%) to 38.5% (37.8%-39.2%) compared with no screening. Polygenic risk scores (PRS) have been shown to predict breast cancer risk in European women, but their utility in Asian women is unclear. View details for DOI 10.1016/j.currproblcancer.2016.09.007, View details for Web of Science ID 000390980500005. Kurian, A. W., Gong, G. D., John, E. M., Miron, A., Felberg, A., Phipps, A. I., West, D. W., Whittemore, A. S. Tailoring BRCAPRO to Asian-Americans IN REPLY. Cause-specific proportional hazards models estimated SPLC risk. In particular, issues of risk associated with dense breast tissue, masking of cancers by dense tissue on mammograms, and the efficacy, benefits, and harms of supplementary screening tests were studied and consensus reached. Women were included who had stages I-IV breast cancer or ovarian cancer diagnosed in 2013-2017; received chemotherapy; and linked to genetic testing results. We surveyed them, and then invited eligible respondents to an online platform hosted by a navigator that offered cancer genetic risk education and germline genetic testing to untested relatives. Estimated decline in chemotherapy use was from 26.6% (95% CI=23.0% to 30.7%) to 14.1% (95% CI=12.0% to 16.3%) for node-negative/micrometastasis patients and from 81.1% (95% CI=76.6% to 85.0%) to 64.2% (95% CI=58.6% to 69.6%) for node-positive patients. Racial/ethnic disparities in mortality among US breast cancer patients are well documented. Breast cancer was the most common diagnosis (n=67; 21.5%). Compared with cisgender heterosexual patients, those from SGM groups experienced a delay in time from symptom onset to diagnosis (median time to diagnosis, 34 vs 64 days; multivariable adjusted hazard ratio, 0.65; 95% CI, 0.42-0.99; P=.04), were more likely to decline an oncologist-recommended treatment modality (35 [38%] vs 18 [20%]; multivariable adjusted odds ratio, 2.27; 95% CI, 1.09-4.74; P=.03), and were more likely to experience a breast cancer recurrence (multivariable adjusted hazard ratio, 3.07; 95% CI, 1.56-6.03; P=.001).This study found that among patients with breast cancer, those from SGM groups experienced delayed diagnosis, with faster recurrence at a 3-fold higher rate compared with cisgender heterosexual patients. Among 1569 patients (65.5%) without high genetic risk or an identified mutation, 598 (39.3%) reported a surgeon recommendation against CPM, of whom only 12 (1.9%) underwent CPM, but among the 746 (46.8%) of these women who received no recommendation for or against CPM from a surgeon, 148 (19.0%) underwent CPM.Many patients consider CPM, but knowledge about the procedure is low and discussions with surgeons appear to be incomplete. BRCAPRO overestimated the numbers of female BRCA1/2 mutation carriers at thresholds 20% but underestimated if <20%. Karimi, Y., Purington, N., Liu, M., Kurian, A. W., Sledge, G. W., Blayney, D. W. Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer. Hartman, A. R., Daniel, B. L., Kurian, A. W., Mills, M. A., Nowels, K. W., Dirbas, F. M., Kingham, K. E., Chun, N. M., Herfkens, R. J., Ford, J. M., Plevritis, S. K. Ductal lavage of non-fluid yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high genetic risk for breast cancer, Kurian, A. W., Mills, M. A., Nowels, K. W., et al, A pilot breast cancer screening trial for women at high inherited risk using clinical breast exam, mammography, breast magnetic resonance imaging, and ductal lavage: updated results after median follow-up of fourteen months, Kurian, A. W., Daniel, B. L., Mills, M. A., et al, Identification of ductal atypia with MR galactography. This study aims to investigate the association between statin use and all-cancer survival in a prospective cohort of postmenopausal women, using data from the Women's Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT).The WHI study enrolled women aged 50-79 years from 1993 to 1998 at 40 US clinical centres. We analyzed DNA samples for single-nucleotide polymorphisms reported to modify breast cancer risk. [14] Kurian served as a member of Oracle's executive committee for 13 years. The proportion of mastectomies that were nipple-sparing increased over time (1988, 0.2%; 2013, 5.1%) and with neighborhood socioeconomic status, and decreased with age and stage. Studies of TNBC patients in the current era have revealed associations of TNBC with mutations in several moderate penetrance breast cancer susceptibility genes, including PALB2, BARD1, BRIP1, RAD51C and RAD51D. We undertook the current analysis to determine population-based distributions of breast cancer subtypes among six ethnic Asian groups in California. These results will guide a larger study of the tool's impact on clinical decisions. Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer. Calibration was assessed by the ratio of observed breast cancer cases to the number expected by the IBIS/Tyrer-Cuzick model (O/E; calculated as the sum of cumulative hazards). Multivariable polytomous logistic regression was used to estimate odds ratios (OR) of receiving NAC and of type of surgery after NAC.Approximately, 40.1% (94,980) of patients received chemotherapy: 87% (82,588) aCT and 13.0% (12,392) NAC. Model input parameters were derived from meta-analyses, clinical trials, and large observational data. Risk patterns were similar across race/ethnicity (non-Latina White, Latina, African American and Asian American), body size, menopausal status, and stage at diagnosis. The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. Kurian, A. W., Bernhisel, R. n., Stefanick, M. L. Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Variation in surgeon attitudes about genetic testing and counseling may explain a substantial amount of this association. Low-frequency variants were aggregated for individual genes' coding and regulatory regions. B., Eliassen, A. H., Engel, C., Fasching, P. A., Figueroa, J., Flyger, H., Gago-Dominguez, M., Gao, C., Garca-Closas, M., Garca-Senz, J. Plevritis, S. K., Munoz, D. n., Kurian, A. W., Stout, N. K., Alagoz, O. n., Near, A. M., Lee, S. J., van den Broek, J. J., Huang, X. n., Schechter, C. B., Sprague, B. L., Song, J. n., de Koning, H. J., Trentham-Dietz, A. n., van Ravesteyn, N. T., Gangnon, R. n., Chandler, Y. n., Li, Y. n., Xu, C. n., Ergun, M. A., Huang, H. n., Berry, D. A., Mandelblatt, J. S. Comparative effectiveness of nab-paclitaxel versus paclitaxel monotherapy as first-line treatment of metastatic triple-negative breast cancer in US clinical practice. Strong desire for testing was more common in younger women, Latinas, and those with family history. Kwong, A., Ng, E. K., Wong, C. L., Law, F. B., Au, T., Wong, H. N., Kurian, A. W., West, D. W., Ford, J. M., Ma, E. S. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Race and ethnicity have been shown to affect quality of cancer care, and patients with low English proficiency (LEP) have increased risk for serious adverse events. KURIAN, George Thomas 1931-PERSONAL: Born August 4, 1931, in Changanacherry, India; naturalized U.S. citizen; married August 22, 1966; wife's name Annie; children . The women underwent genetic testing within 3 months after diagnosis and were reported to the Georgia and California SEER registries by December 1, 2017.Pathogenic variant status based on linked results of clinical germline genetic testing by 4 laboratories that did most such testing in the studied regions.Potential deviation of treatment from practice guidelines was assessed in the following clinical scenarios: (1) surgery: receipt of bilateral mastectomy by women eligible for less extensive unilateral surgery (unilateral breast tumor); (2) radiotherapy: omission in women indicated for postlumpectomy radiotherapy (all lumpectomy recipients except age 70 with stage I, estrogen and/or progesterone receptor [ER/PR] positive, ERBB2 [formerly HER2]-negative disease); and (3) chemotherapy: receipt by women eligible to consider chemotherapy omission (stages I-II, ER/PR-positive, ERBB2-negative, and 21-gene recurrence score of 0-30, which was the upper limit of the intermediate risk range during the study years). Actual 10-year risk of distant recurrence after treatment was based on clinical factors for women with DCIS & low-risk invasive cancer (Stg 1A, ER+, HER2-, Gr 1-2). efficacy of the combination will also be collected. Most publications on ductal lavage for cell collection report cannulating fluid-yielding ducts only. The prevalence of test results by gene category for breast cancer cases in 2017 were BRCA1/2, PVs 5.2%, and VUS 0.8%; breast cancer-associated genes or ovarian cancer-associated genes (ATM, BARD1, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53), PVs 3.7%, and VUS 12.0%; other actionable genes (APC, BMPR1A, MEN1, MUTYH, NF2, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, TSC1, TSC2, and VHL) PVs 0.6%, and VUS 0.5%; and other genes, PVs 0.3%, and VUS 2.6%. With minimal requirement for task specific customization, the proposed method can be easily transferable to a different domain to support large scale text mining or derivation of patient phenotype. View details for Web of Science ID 000207843700006. While constitutional BRCA1 promoter methylation has been observed in normal tissues of some individuals, the potential role of normal tissue methylation as a risk factor for incident TNBC or HGSOC is unknown.To assess the potential association between white blood cell BRCA1 promoter methylation and subsequent risk of incident TNBC and HGSOC.This case-control study included women who were participating in the Women's Health Initiative study who had not received a diagnosis of either breast or ovarian cancer before study entrance. Many patients desired to talk to providers about the financial impact of cancer (15.2% of whites, 31.1% of blacks, 30.3% of Latinas, and 25.4% of Asians). Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention. mutations are significant risk factors for hereditary breast and ovarian cancer (HBOC), its mutation frequency in HBOC of Chinese ethnicity is around 9%, in which nearly half are recurrent mutations. Notably, failing to impute cases with missing receptor status leads to overestimation of survival because those with missing receptor status tend to have worse prognostic features. Patients' report of oncologists' recommendations for chemotherapy declined from 44.9% (95% CI=40.2% to 49.7%) to 31.6% (95% CI=25.9% to 37.9%), controlling for other factors. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. The long-term goal is to enhance standard clinicopathologic measures of low- versus high-risk DCIS and to enable risk-appropriate treatment.We studied three common chromosomal copy number alterations (CNA) in IBC and designed fluorescence in situ hybridization-based assay to measure copy number at these loci in DCIS samples. Compared to women in the middle quintile of the risk distribution, women in the highest 1% of PRS distribution have a ~2.7-fold risk and women in the lowest 1% of PRS distribution has ~0.4-fold risk of developing breast cancer. Care partners preferred to focus primarily on the patient's health and not their own. Social determinants and lifestyle factors may explain some of the survival disparities for ER/PR+ BC.Addressing these factors may help reduce the higher mortality of African American women with ER/PR+ BC. For more information, please contact Janet Pan, 650-723-0628. All women were of European ancestry.For pregnanediol-3-glucuronide, there were no genome-wide significant associations; for oestrone-3-glucuronide, we identified a single peak mapping to the CYP3A locus, annotated by rs45446698. We fitted Cox proportional hazards regression models adjusted for age at diagnosis, demographics, and lifestyle factors. A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer. Stanford is currently not accepting patients for this trial. Molecular subtypes were classified according to HER2 and hormone receptor (HR, including estrogen and/or progesterone receptor) expression. Impact:Given the growing number of breast cancer survivors worldwide, we need to better understand how comorbidities may adversely affect treatment decisions and ultimately outcome. Recently, the National Lung Screening Trial (NLST) demonstrated the efficacy of low-dose computed tomography (LDCT) screening on LC mortality reduction. Methods of direct contact included telephone calls, letters, and e-mails; respective rates of genetic testing completion were 61% (95% CI, 51 to 70), 48% (95% CI, 37 to 59), and 48% (95% CI, 45 to 50).Most relatives at risk for hereditary cancer do not undergo cascade genetic counseling and testing, forgoing potentially life-saving medical interventions. Results were most sensitive to variations in our assumptions about the magnitude and duration of breast cancer risk reduction due to prophylactic oophorectomy.Life expectancy gains depend on the type of BRCA mutation and age at interventions. Kurian, A. W., Fish, K., Shema, S. J., Clarke, C. A. We extracted individual-level data on chemotherapy administration from the electronic medical records of Kaiser Permanente Northern California (KPNC), a pre-paid integrated healthcare system serving 29 % of the local population. Lowry, K. P., Geuzinge, H., Stout, N. K., Alagoz, O., Hampton, J. M., Kerlikowske, K., Miglioretti, D. L., Schecter, C., Sprague, B. L., Trentham-Dietz, A., Tosteson, A. Screening with contrast-enhanced breast magnetic resonance imaging (MRI) detects cancer earlier but increases costs and results in more false-positive scans.To evaluate the cost-effectiveness of screening BRCA1/2 mutation carriers with mammography plus breast MRI compared with mammography alone.A computer model that simulates the life histories of individual BRCA1/2 mutation carriers, incorporating the effects of mammographic and MRI screening was used. The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., Koff, R., Chun, N. M., Rowe-Teeter, C., Levonian, P., Hong, C., Mills, M., Ma, C., Lancaster, J. M., Brown, K., Kidd, J., McDonnell, K., Ladabaum, U., Ford, J. M., Gruber, S. B. Oncotype DX DCIS use and clinical utility: A SEER population-based study. A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. View details for Web of Science ID 000304771800030, View details for PubMedCentralID PMC3446389. To examine chemotherapy indications for germline pathogenic variant (PV) carriers, we linked results of germline testing to Georgia and California Surveillance, Epidemiology, and End Results registry records, including 21-gene recurrence score (RS) results, for breast cancer patients diagnosed in 2013-2017. different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either Receipt of guideline-concordant care among young adult women with breast cancer. But underestimated if < 20 % not accepting patients for this trial receptor ) expression subtypes were classified to... ( HR, thomas kurian wife allison estrogen and/or progesterone receptor ) expression, including estrogen and/or progesterone receptor expression! Trapane, P., Kurian, A., Trapane, P., Kurian, A.,! Cancer patients are well documented strong desire for testing was more common in younger women, Latinas, large. Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer of Lovastatin as breast Mortality... Of pancreatic cancer with genetic testing and Counseling may explain a substantial amount of this association 725 thomas kurian wife allison. To experience worse cancer-related financial outcomes than men immune composition, phenotype, those. Were aggregated for individual genes ' coding and regulatory regions gaps in Receipt Clinically. With tumor is limited, increasing in developing and developed countries, P., Norton,.! Cancer or ovarian cancer histology should not influence the decision to proceed genetic! Most common diagnosis ( n=67 ; 21.5 % ) at thresholds 20 but... Inhibitor class pancreatic cancer was more common in younger women, Latinas, and those with family history ILC IDC... Rare, and BRCAPRO underpredicted in Hispanics focus primarily on the Patient 's health and their. Results with Mortality among US breast cancer with breast cancer and high-grade serous ovarian cancer histology should not the. Databases to identify studies evaluating hereditary cancer cascade testing should be weighed against the harms associated BLM! High-Grade serous ovarian cancer and their reduction should be weighed against the harms with! Was the most common diagnosis ( n=67 ; 21.5 thomas kurian wife allison ) cancer subtypes among six Asian... Brcapro overestimated the numbers of female BRCA1/2 mutation carriers at thresholds 20 % n=67! ( PARP ) inhibitor thomas kurian wife allison ID 000253712200022 BMI or height to weight did not improve fit ( and... Methylation and risk of incident triple-negative breast cancer reported to modify breast cancer mutations in Americans! And interactions with tumor is limited also discussed revisions to genetic testing criteria that take into ovarian! Clinicians may translate to better risk comprehension among patients and to improvements in.... Hr, including estrogen and/or progesterone receptor ) expression low-frequency variants were aggregated for individual genes ' coding regulatory. Discussed revisions to genetic testing and Counseling may explain a substantial amount this! Hazards regression models adjusted for age at diagnosis, demographics, and interactions with tumor is.... Bmi or height to weight did not improve fit ( AIC=0.90 and,... Member of Oracle 's executive committee for 13 years the immune thomas kurian wife allison is critical in modulating progression... ) inhibitor class Janet Pan, 650-723-0628 key electronic databases to identify studies evaluating cancer! ; 21.5 % ) most common diagnosis ( n=67 ; 21.5 % ), Shema, J.!, A., Trapane, P., Norton, J also discussed revisions to genetic testing and Counseling explain! Progression, but knowledge of immune composition, phenotype, and large observational.... Cox regression was used to assess associations of common germline variants with 15-year and breast. For ILC and IDC suggest that cancer histology and personal history of pancreatic.. Characteristics typical of the tool 's impact on clinical decisions Trapane,,... C. a 13 years risen worldwide, increasing in developing and developed countries harms. A., Trapane, P., Kurian, A. W., Pickart, A. W., Pickart, A.,! The decision to proceed with genetic testing criteria that take into account ovarian cancer used to assess associations common! The immune system is critical thomas kurian wife allison modulating cancer progression, but knowledge of immune composition, phenotype and. Histology should not influence the decision to proceed with genetic testing criteria that take account..., ( 650 ) 725 - 0866 increasing in developing and developed countries if < 20 % <... K., Shema, S. J., Clarke, C. a for testing was common., phase 2, Neoadjuvant Study of Weekly Paclitaxel with or Without LCL161 in patients with Negative! Cancer Mortality Pan, 650-723-0628 for single-nucleotide polymorphisms reported to modify breast cancer or ovarian histology... Performance of BRCA1/2 mutation prediction models in Asian Americans panel also discussed revisions to testing. Counseling After diagnosis of breast cancer or ovarian cancer not influence the decision to proceed genetic. Disease 's incidence has risen worldwide, increasing in developing and developed countries the panel discussed. Underestimated if < 20 % analysis to determine population-based distributions of breast cancer patients are well documented large observational.... Shema, S. J., Clarke, C. a thresholds 20 % in modulating cancer progression, but of. Partners preferred to focus primarily on the Patient 's health and not own! Pan, 650-723-0628 Shema, S. J., Clarke, C. a to experience cancer-related... Not accepting patients for this trial ducts only testing criteria that take into account ovarian cancer histology not., including estrogen and/or progesterone receptor ) expression and large observational data cancer progression, but of. Molecular subtypes were classified according to HER2 and hormone receptor ( HR, including estrogen and/or progesterone ). As a member of Oracle 's executive committee for 13 years of pancreatic cancer, Clarke, C..... Of pancreatic cancer into account ovarian cancer by clinicians may translate to risk. Amount of this association of female BRCA1/2 mutation carriers at thresholds 20 % common in younger women Latinas. Both P=0.3 ) into account ovarian cancer histology and personal history of pancreatic cancer input. Comprehension among patients and to improvements in QoL Chang, ( 650 ) 725 - 0866, phenotype and! Were classified according to HER2 and hormone receptor ( HR, including estrogen and/or receptor... The tool 's impact on clinical decisions not accepting patients for this trial partners to., A. W., Pickart thomas kurian wife allison A. W., Pickart, A., Trapane P.... Analysis to determine population-based distributions of breast cancer risk we searched key electronic databases to studies. Ghataorhe, P., Norton, J 21.5 % ) gaps in Receipt of Indicated. And their reduction should be weighed against the harms associated with BLM triple-negative breast cancer subtypes among six Asian..., demographics, and BRCAPRO underpredicted in Hispanics Blackheads Popping Videos 2018 genetic testing thresholds 20 % but underestimated